BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

...Louis, Mo. Targets BECN1 (ATG6) - Beclin-1 TFEB - Transcription factor EB TORC1 (CRTC1) - CREB regulated transcription coactivator 1...
BioCentury | Jan 5, 2018
Financial News

resTORbio proposes $85M IPO

...raised to $65 million (see BioCentury, Dec. 1, 2017 ). resTORbio Inc., Boston, Mass. Jennie Walters RTB101 resTORbio Inc. CREB regulated transcription coactivator 1...
BioCentury | Dec 1, 2017
Financial News

resTORbio raises $40M series B

...is to enroll 424 patients. resTORbio expects top-line data in 2H18. RTB101 is an oral CREB regulated transcription coactivator 1...
...diluted basis. OrbiMed's Jonathan Silverstein joined resTORbio's board. resTORbio Inc., Boston, Mass. Jaime De Leon Afinitor everolimus RTB101 Novartis AG resTORbio Inc. CREB regulated transcription coactivator 1...
BioCentury | Nov 30, 2017
Financial News

resTORbio raises $40M

...is to enroll 424 patients. resTORbio expects top-line data in 2H18. RTB101 is an oral CREB regulated transcription coactivator 1...
...on a fully diluted basis. OrbiMed's Jonathan Silverstein joined resTORbio's board. Jaime De Leon Novartis AG PureTech Health plc CREB regulated transcription coactivator 1...
BioCentury | Jul 21, 2014
Finance

Highlights of weekly biotech stock moves

...shares, with each whole warrant exercisable at $4.80. RestorGenex's P529 , a dual inhibitor of CREB regulated transcription coactivator 1...
BioCentury | Jul 16, 2014
Financial News

RestorGenex raises $35.6 million

...focus on dermatology, ocular diseases and women's health. RestorGenex's P529 , a dual inhibitor of CREB regulated transcription coactivator 1...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) CREB-regulated transcription coactivator 1 (CRTC1; TORC1) Human and mouse studies suggest agonizing CRTC1 could help treat AD. In patients with intermediate and...
BioCentury | Mar 17, 2014
Company News

Paloma, RestorGenex, VasculoMedics deal

...AKT; AKT1) pathway. The company's Palomid 529 ( P529 ) is a dual inhibitor of CREB regulated transcription coactivator 1...
BioCentury | Jun 10, 2013
Emerging Company Profile

ONL Therapeutics: Eyeing Fas

...investigational retinal detachment therapeutics include Paloma Pharmaceuticals Inc. 's Palomid 529 , an inhibitor of CREB regulated transcription coactivator 1...
BioCentury | Mar 14, 2011
Clinical News

Paloma preclinical data

...PI3K / mTOR Signaling in Cancer in San Francisco. The dual, synthetic, non-steroidal inhibitor of CREB regulated transcription coactivator 1...
Items per page:
1 - 10 of 18